Non-alcoholic Fatty Liver Disease
-
Subject Areas on Research
-
A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease.
-
A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease.
-
A Western diet induced NAFLD in LDLR(-/)(-) mice is associated with reduced hepatic glutathione synthesis.
-
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.
-
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.
-
A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques.
-
A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
-
A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease.
-
Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.
-
Acetyl-CoA metabolism drives epigenome change and contributes to carcinogenesis risk in fatty liver disease.
-
Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease.
-
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
-
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
-
Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children.
-
Altered branched-chain α-keto acid metabolism is a feature of NAFLD in individuals with severe obesity.
-
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
-
An MMP-degraded and cross-linked fragment of type III collagen as a non-invasive biomarker of hepatic fibrosis resolution.
-
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.
-
Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
-
Association between puberty and features of nonalcoholic fatty liver disease.
-
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
-
Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease.
-
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
-
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.
-
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
-
Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
-
Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.
-
Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study.
-
CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis.
-
Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.
-
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
-
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
-
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
-
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
-
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
-
Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome.
-
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
-
Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease.
-
Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease.
-
Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.
-
Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease.
-
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.
-
Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.
-
Cross-linkage between bacterial taxonomy and gene functions: a study of metagenome-assembled genomes of gut microbiota in adult non-alcoholic fatty liver disease.
-
Current status of fibrosis markers.
-
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.
-
Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease.
-
De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.
-
Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies.
-
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
-
Delayed Sleeve Gastrectomy Following Liver Transplantation: A 5-Year Experience.
-
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
-
Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression.
-
Direct effects of thyroid hormones on hepatic lipid metabolism.
-
Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.
-
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
-
Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.
-
Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression.
-
Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?
-
Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply.
-
Editorial: re-thinking cardiovascular risk factors in NAFLD with advanced fibrosis? Authors' reply.
-
Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients With NASH.
-
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
-
Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21.
-
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus.
-
Extracardiac Abnormalities of Preload Reserve: Mechanisms Underlying Exercise Limitation in Heart Failure with Preserved Ejection Fraction, Autonomic Dysfunction, and Liver Disease.
-
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
-
Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.
-
Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.
-
Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis.
-
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.
-
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
-
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.
-
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
-
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
-
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.
-
Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis.
-
Granulocytic MDSC with Deficient CCR5 Alleviates Lipogenesis and Inflammation in Nonalcoholic Fatty Liver Disease.
-
HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
-
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.
-
Hedgehog pathway and pediatric nonalcoholic fatty liver disease.
-
Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.
-
Hepatic HKDC1 Expression Contributes to Liver Metabolism.
-
Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b.
-
Hepatic Lipid Catabolism via PPARα-Lysosomal Crosstalk.
-
Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.
-
Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
-
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.
-
Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
-
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.
-
Hepatocyte-specific IL11 cis-signaling drives lipotoxicity and underlies the transition from NAFLD to NASH.
-
High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease.
-
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.
-
Hormone signaling and fatty liver in females: analysis of estrogen receptor α mutant mice.
-
How bariatric surgery affects liver volume and fat density in NAFLD patients.
-
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH.
-
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
-
Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
-
Implication of gut microbiota in nonalcoholic fatty liver disease.
-
Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention.
-
Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.
-
Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.
-
Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy.
-
Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
-
Intricate interpretation of etiology-specific outcome comparison in patients with hepatocellular carcinoma.
-
Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin.
-
Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart.
-
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.
-
Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.
-
Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis.
-
Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men.
-
Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.
-
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.
-
Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis.
-
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.
-
M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.
-
MED1 mediator subunit is a key regulator of hepatic autophagy and lipid metabolism.
-
Machine Learning Approach to Classify Cardiovascular Disease in Patients With Nonalcoholic Fatty Liver Disease in the UK Biobank Cohort.
-
Measuring acetyl-CoA and acetylated histone turnover in vivo: Effect of a high fat diet.
-
Mechanisms of disease progression in NASH: new paradigms.
-
Meta-Analysis of Nonalcoholic Fatty Liver Disease and Incident Heart Failure.
-
Metabolic liver disease - what's in a name?
-
Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet.
-
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis.
-
Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.
-
Monitoring Fatty Liver Disease with MRI Following Bariatric Surgery: A Prospective, Dual-Center Study.
-
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.
-
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
-
Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis.
-
NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment.
-
NAFLD and extrahepatic cancers: have a look at the colon.
-
NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition.
-
NAFLD, NASH and liver cancer.
-
NASH in HIV.
-
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.
-
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
-
NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.
-
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
-
Non-Alcoholic Fatty Liver Disease, Heart Failure, and Long-Term Mortality: Insights From the National Health and Nutrition Examination Survey.
-
Non-alcoholic fatty liver diseases and risk of colorectal neoplasia.
-
Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes.
-
Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
-
Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.
-
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.
-
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries.
-
Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
-
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
-
Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.
-
Nonalcoholic Steatohepatitis.
-
Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
-
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.
-
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.
-
Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease.
-
Novel Transcriptional Mechanisms for Regulating Metabolism by Thyroid Hormone.
-
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
-
Obese humans with nonalcoholic fatty liver disease display alterations in fecal microbiota and volatile organic compounds.
-
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
-
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.
-
Outcomes of Liver Transplantation Among Older Recipients With Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the Re-Evaluating Age Limits in Transplantation Consortium.
-
PPDPF alleviates hepatic steatosis through inhibition of mTOR signaling.
-
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma.
-
Pathogenesis of Nonalcoholic Steatohepatitis.
-
Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.
-
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.
-
Perceptions of Exercise and Its Challenges in Patients With Nonalcoholic Fatty Liver Disease: A Survey-Based Study.
-
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.
-
Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.
-
Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
-
Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease.
-
Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine.
-
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
-
Prospective comparison of longitudinal change in hepatic proton density fat fraction (PDFF) estimated by magnitude-based MRI (MRI-M) and complex-based MRI (MRI-C).
-
Purinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitis.
-
Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.
-
Recent advances in nonalcoholic fatty liver disease metabolomics.
-
Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
-
Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.
-
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
-
Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
-
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
-
Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease.
-
Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.
-
Reply to Kim et al.
-
Reply to: "B vitamins for NASH: Use methylcobalamin, not cyanocobalamin".
-
Reply.
-
Reply.
-
Reply.
-
Reply.
-
Reply.
-
Reply: To PMID 24849310.
-
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
-
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
-
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
-
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
-
Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
-
Role of Hedgehog Signaling Pathway in NASH.
-
Screening for metabolic and reproductive complications in obese children and adolescents.
-
Serum Bile Acid, Vitamin E, and Serotonin Metabolites Are Associated With Future Liver-Related Events in Nonalcoholic Fatty Liver Disease.
-
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.
-
Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.
-
Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD.
-
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
-
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease.
-
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.
-
Spermidine-mediated hypusination of translation factor EIF5A improves mitochondrial fatty acid oxidation and prevents non-alcoholic steatohepatitis progression.
-
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.
-
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
-
Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation.
-
Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis.
-
Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.
-
Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development.
-
TRPV4 activation of endothelial nitric oxide synthase resists nonalcoholic fatty liver disease by blocking CYP2E1-mediated redox toxicity.
-
Tackling Nonalcoholic Fatty Liver Disease: Three Targeted Populations.
-
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
-
Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD.
-
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
-
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
-
The association of impaired lung function and nonalcoholic fatty liver disease: a systematic review.
-
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
-
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
-
The hedgehog pathway in nonalcoholic fatty liver disease.
-
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
-
The role of bariatric surgery in the management of nonalcoholic steatohepatitis.
-
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
-
Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis.
-
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
-
Towards a definite mouse model of NAFLD.
-
Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C.
-
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
-
Trends in statin utilisation in US adults with non-alcoholic fatty liver disease.
-
Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.
-
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
-
Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
-
Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
-
Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing syntaxin 17 homocysteinylation.
-
Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
-
Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.
-
Wearables, Physical Activity, and Exercise Testing in Liver Disease.
-
Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
-
Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease.
-
Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome.
-
Keywords of People
-
Alexopoulos, Anastasia Stefania,
Assistant Professor of Medicine,
Medicine, Endocrinology, Metabolism, and Nutrition
-
Dinani, Amreen,
Associate Professor of Medicine,
Medicine, Gastroenterology
-
Liao, Tzu-chieh,
Student,
Immunology